| 78.105 0.53 (0.68%) | 11-18 15:59 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 92.2 | 1-year : | 107.69 |
| Resists | First : | 78.94 | Second : | 92.2 |
| Pivot price | 76.13 |
|||
| Supports | First : | 73.92 |
Second : | 70.83 |
| MAs | MA(5) : | 77.92 |
MA(20) : | 75.46 |
| MA(100) : | 69.76 |
MA(250) : | 67.13 |
|
| MACD | MACD : | 1.6 |
Signal : | 1.4 |
| %K %D | K(14,3) : | 83.5 |
D(3) : | 84.1 |
| RSI | RSI(14): 67.7 |
|||
| 52-week | High : | 78.94 | Low : | 54.52 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ PBE ] has closed below upper band by 22.9%. Bollinger Bands are 71.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 78.27 - 78.65 | 78.65 - 78.97 |
| Low: | 76.18 - 76.63 | 76.63 - 77.01 |
| Close: | 77.44 - 78.13 | 78.13 - 78.72 |
PBE is not a pure-play biotech fund, it goes beyond the scope of pure biotech firms and includes companies that benefit significantly from advances in biotech and genetic engineering. This causes PBE to differ from other biotech ETFs, therefore, it is important to note the funds portfolio before investing. Moreover, far from a plain-vanilla approach, PBE's underlying index uses a multifactor system (price momentum, earnings momentum, quality: ROE, asset turnover, FCF margin), management action, and value) to select 30 US stocks and weights them in tiers. The tiered weighting scheme creates a small-cap tilt. Top-ranked larger stocks receive 40% of index weight while the top-ranked smaller stocks are given 60%. The approach produces a unique portfolio of biotech and peripheral-industry companies. The fund is rebalanced and reconstituted quarterly starting each February. Prior to August 28, 2023, the fund traded under the name Invesco Dynamic Biotechnology & Genome ETF.
Tue, 18 Nov 2025
2 ETFs to Watch for Outsized Volume on Biotechnology Stocks - Zacks Investment Research
Thu, 02 Oct 2025
The Best Biotech ETFs to Buy - Kiplinger
Sat, 27 Sep 2025
Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk - Benzinga
Fri, 19 Sep 2025
Invesco Biotechnology & Geno Funds To Go Ex-Dividend On September 22nd, 2025 With 0.23409 USD Dividend Per Share - 富途牛牛
Tue, 26 Aug 2025
China’s biotech breakthrough: From generics to global intellectual property - invesco.com
Wed, 13 Aug 2025
7 Best Biotech ETFs to Buy Now - US News Money
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
AMEX
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|